Biosimilar Aflibercept

About Organon (2)

Organon is a mission-driven global healthcare company established in 2021 as a spin-off from Merck & Co., with a dedicated focus on women's health. Its strategy is built on three core pillars: advancing a portfolio of women's health therapies, expanding access through biosimilars, and maximizing the value of a broad range of established medicines. The company has achieved immediate global scale, operating in over 140 markets, and is recognized for its strong corporate governance and commitment to addressing healthcare inequities.

About Sandoz

Sandoz, spun off from Novartis in October 2023, is a global champion in the off-patent pharmaceuticals market, dedicated to its social mission of expanding access to medicine. It achieves this through a dual-pillar strategy: a broad portfolio of generic drugs and a rapidly growing, scientifically advanced biosimilars franchise. As an independent public entity, Sandoz is now positioned to accelerate growth, optimize its capital structure, and directly capitalize on the significant long-term tailwinds in both the generics and biosimilars sectors worldwide.

Therapeutic Areas